Renin–angiotensin system regulates neurodegeneration in a mouse model of normal tension glaucoma
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Glaucoma, one of the leading causes of irreversible blindness, is characterized by progressive degeneration of optic nerves and retinal ganglion cells (RGCs). In the mammalian retina, excitatory amino acid carrier 1 (EAAC1) is expressed in neural cells, including RGCs, and the loss of EAAC1 leads to RGC degeneration without elevated intraocular pressure (IOP). In the present study, we found that expressions of angiotensin II type 1 receptor (AT1-R) and Toll-like receptor 4 (TLR4) are increased in RGCs and retinal Müller glia in EAAC1-deficient (KO) mice. The orally active AT1-R antagonist candesartan suppressed TLR4 and lipopolysaccharide (LPS)-induced inducible nitric oxide synthase (iNOS) expressions in the EAAC1 KO mouse retina. Sequential in vivo retinal imaging and electrophysiological analysis revealed that treatment with candesartan was effective for RGC protection in EAAC1 KO mice without affecting IOP. In cultured Müller glia, candesartan suppressed LPS-induced iNOS production by inhibiting the TLR4-apoptosis signal-regulating kinase 1 pathway. These results suggest that the renin-angiotensin system is involved in the innate immune responses in both neural and glial cells, which accelerate neural cell death. Our findings raise intriguing possibilities for the management of glaucoma by utilizing widely prescribed drugs for the treatment of high blood pressure, in combination with conventional treatments to lower IOP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lehnardt, S., Massillon, L., Follett, P., Jensen, F. E., Ratan, R., Rosenberg, P. A., Volpe, J. J., & Vartanian, T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432609100 · Cited by 1,052
Matsuzawa, A., Saegusa, K., Noguchi, T., Sadamitsu, C., Nishitoh, H., Nagai, S., Koyasu, S., Matsumoto, K., Takeda, K., & Ichijo, H. (2005) · Nature Immunology · doi:10.1038/ni1200 · Cited by 667
Müller Glial Cells in Retinal Disease
Bringmann, A., & Wiedemann, P. (2012) · Ophthalmologica · doi:10.1159/000328979 · Cited by 436
Harada, T., Harada, C., Kohsaka, S., Wada, E., Yoshida, K., Ohno, S., Mamada, H., Tanaka, K., Parada, L. F., & Wada, K. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09228.2002 · Cited by 397 · cited 1×
“Müller cells were isolated as previously reported.(41,43) Müller cells derived from WT and ASK1 KO mice were stimulated with AngII (0, 10, 100 and 1000 nM) for 24 h and/or LPS (0, 0.”
MethodSelf-citationDock3 induces axonal outgrowth by stimulating membrane recruitment of the WAVE complex
Namekata, K., Harada, C., Taya, C., Guo, X., Kimura, H., Parada, L. F., & Harada, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914514107 · Cited by 84
Self-citation
Cited by
Neuroprotection in Glaucoma: Animal Models and Clinical Trials
Almasieh, M., & Levin, L. A. (2017) · Annual Review of Vision Science · doi:10.1146/annurev-vision-102016-061422 · Cited by 111
“…findings that intraocular application of drugs such as ibudilast (a cAMP phosphodiesterase inhibitor) (Cueva Vargas et al. 2016) or candesartan (an angiotensin II type 1 receptor antagonist) (Semba et al. 2014) significantly improved RGC survival in glaucoma by suppressing Müller-cell activation.”
BackgroundDock GEFs and their therapeutic potential: Neuroprotection and axon regeneration
Namekata, K., Kimura, A., Kawamura, K., Harada, C., & Harada, T. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.06.005 · Cited by 57
Self-citationPhipps, J. A., Dixon, M. A., Jobling, A. I., Wang, A. Y., Greferath, U., Vessey, K. A., & Fletcher, E. L. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.107753 · Cited by 48
Metadata
- Authors
- Semba, K., Namekata, K., Guo, X., Harada, C., Harada, T., & Mitamura, Y.
- Venue
- Cell Death & Disease
- Published
- 2014-07-17
- Volume
- 5
- Issue
- 7
- Pages
- e1333-e1333
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2043764841
- Cited by
- 57
- References
- 5
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.